
News|Articles|June 1, 2010
Formulary Digital Edition, June 2010
Pulmonary arterial hypertension: Bridging the gap between efficacy, quality of life, and cost-effectiveness; Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity; Vaccine agents in late-stage development.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?
2
FDA approves first postmenopausal libido treatment, Addyi
3
Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk
4
Pharmacy leaders in ASHP survey worry about 340B program changes
5






















































